25.09.2018 – More investment funds and new investment profiles in the limelight at BIOSPAIN 2018

 In notas de prensa
  • The 9th International Meeting on Biotechnology BIOSPAIN 2018 starts in Seville
  • Johnson & Johnson, Lilly, MSD and Novartis participate in the Big-Pharma presentations sessions for discussing innovation, association formulas and collaboration with other agents in the system and finding opportunities for agreements and licences Andalusia is the third largest Autonomous Community for companies devoted solely to biotechnology and the second largest in hosting companies that undertake biotechnology activities
  • The top ten investment funds attending BIOSPAIN 2018 manage over 8 billion euros in assets in life sciences
  • This ninth edition expects to welcome 50 investors to analyse 40 biotechnological projects at the Investment Forum

Seville, 25 September 2018.- The ninth edition of the International Meeting on Biotechnology BIOSPAIN 2018 (http://www.biospain2018.org) will take place at the FIBES Exhibition & Congress Centre on 25-27 September in the Andalusian capital. Coinciding with European Biotechnology Week (http://www.biotechweek.org/), the event is organised by the Spanish Association of Biotech Companies (ASEBIO) and the Regional Government of Andalusia through a Steering Committee representing the Regional Ministries of Knowledge, Research and University; Health; Employment, Business and Trade; and Agriculture, Fishing and Rural Development.

This Steering Committee is led by the Innovation and Development Agency of Andalusia (IDEA) and enjoys the participation of the Regional Ministry of Agriculture, the Andalusian Knowledge Agency and the Progress and Health Foundation, the latter two on behalf of their regional ministries.

The biomedical area, agri-food and industrial biotechnology and the access to funding are the cornerstone of BIOSPAIN 2018. Advanced therapies, biobanks, the circular economy, artificial intelligence, genetic editing, immunotherapy, precision medicine and antibiotic resistance are just some of the topics that will be addressed in the programme.

This edition will gather over 600 companies from 30 countries and almost 50 of Europe’s most important investors in life sciences. Ysios Capital Partners, Forbion Capital, Fund+, Johnson & Johnson Innovation, Kreos Capital, Medicxi and M Ventures are some of these investors, the main players in financial transactions that enable the continuous growth and development of the Spanish biotechnology business.

In this regard, it should be highlighted that the top ten investment funds attending BIOSPAIN 2018 manage over 8 billion euros in assets in the field of life sciences.

In addition, the principal biotechnology companies will come to Seville to present the latest developments in their research. For the first time, a big pharma group, which includes Johnson & Johnson, Lilly, MSD and Novartis, will receive the opportunity to introduce its projects with the aim of seeking new channels of collaboration with biotech start-ups.

“BIOSPAIN 2018 aims to highlight our biotechnological ecosystem in the eyes of national and international investors and market actors. Grouping all the elements of the biotechnological ecosystem in the same location and attracting the principal investors and leading companies at global scale, we have made BIOSPAIN the principal platform for energisation of international funding and business collaborations at the service of the Spanish biotech industry”, Ion Arocena, the General Manager of ASEBIO, explained at the press conference presenting the event in Seville.


Andalusia on the rise in the biotechnology sector

Ten years after BIOSPAIN 2008, which was held in Granada, this high-level Forum is now doubling its figures for exhibitors, attendees, number of businesses. It has even trebled the number of partnering meetings.

It is undeniable that Andalusia has become one of the most important regions in the field of biotechnology in Spain. It is the third largest Autonomous Community for companies devoted solely to biotechnology, with 16% of the Spanish total. It trails only Catalonia (23.3%) and Madrid (18.7%), and is ahead of the Region of Valencia, which has 10%, according to figures from the ASEBIO Report 2017. Furthermore, it is the second largest in hosting companies that undertake biotechnology work irrespective of whether this is their principal activity, with 13.5% of the Spanish total. The leader is Catalonia, with 19.3%.

Manuel Torralbo, the General Secretary for Universities, Research and Technology of the Regional Government of Andalusia, underlined the commitment of the Andalusian Government, as the event sponsor, to promoting this trade fair and to “providing maximum encouragement for the participation of the sector’s companies and Andalusian R&D&i entities, particularly the region’s public universities, which possess great R&D potential in the biotechnological sphere”. With regard to the participation of the Regional Government of Andalusia, Mr Torralbo highlighted the holding this Thursday of the preliminary market consultation on Public Innovative Procurement in Andalusia as part of the Andalusian Public Procurement Strategy approved recently by the Regional Government, an activity open to those entities wishing to attend.

The developments presented at BIOSPAIN 2018 reflect the sector’s commitment to R&D&i. The impact on the economy of the companies that are fully devoted to biotechnology in 2017 was 7.3 billion euros, which represents around 0,7% of Gross Domestic Product (GDP). It also resulted in the creation of over 108,000 jobs, of which over 22,600 are direct ones.

As a new feature, we have wanted to boost the presence of researchers, academics and representatives of interface bodies through a special registration policy. In this regard, Rafael Solana, the General Secretary for Research, Development and Innovation of the Regional Government of Andalusia, emphasised the importance of BIOSPAIN “as a meeting point for professionals and companies in the area of research. Combining efforts and strengthening collaboration among the agents involved in the generation of knowledge (universities, institutions, the business sector etc.) is a solid base for guaranteeing research, development and innovation in Andalusia”, said Mr Solana, who in his speech announced some of the results achieved by the Andalusian Public Health Service. He also said that the work of the researchers had resulted in more than 1,000 applications for industrial and intellectual property rights and over 450 collaboration agreements with biotechnological companies for the development of new products and technologies.

BIOSPAIN brings together representatives from biotechnological and pharmaceutical companies, research institutes, universities, clusters, investors, professional and advisory services, medical technology companies, engineering companies etc.

For Julio Coca, the General Manager of the IDEA Agency, “the biotechnological sector is a strategic one for the Andalusian economy due to its capacity of sustained growth and high added value, together with its influence on other key productive sectors in the region, such as the agri-industry and medicine. This explains why it is one of the priority sectors for the attracting of investment”. Mr Coca added that the IDEA Agency, which is attached to the Regional Ministry of Employment, Business and Trade, provides a comprehensive service to the investor that includes incentives, funding, areas of excellence, infrastructure and advanced services (some of them specialised in investors from beyond Andalusia).



Agrobiotechnology forum, Early Stage Financing & impact investment in biotechnology, Foodbiotech & Bioprocess and Big-Pharma presentations are some of the notable sessions on Tuesday 25 September. As a plenary session, Marta E. Alarcón Riquelme, a researcher from the Regional Ministry of Health in Genyo (Granada) and the coordinator of the European project, PRECISESADS-IMI, will present the results of her group. These are aimed at the “reclassification of systemic autoimmune diseases” like lupus, rheumatoid arthritis and others based on the identification of new genes involved in these diseases.

The following day, there will be the session Industrial Biotechnology & Circular Economy Forum, Artificial Intelligence: how your company can take advantage of it?, the session Immunotherapy (CART-T y Monoclonal Antibodies) and the plenary session given by Philippe Monteyne, a partner de Fund+ (Belgium).

On the 27th, there will be a discussion of Precision Medicine. Finally, there will be presentation of the strategy for Public Innovative Procurement in Andalusia. This session is especially important as it is the first public market consultation within the framework of the Strategy for the Fostering and Consolidation of Public Innovative Procurement in the Administration of the Regional Government of Andalusia. This session will present for a preliminary market consultation the projects approved by the Regional Ministry of Agriculture and the Regional Ministry of Health in a format that is open to all those companies wishing to participate in these projects for public innovative procurement.


The previous edition in figures

The previous edition, BIOSPAIN 2016, took place in Bilbao and coincided with European Biotechnology Week. It boasted the participation of 45 national and international investment funds, 233 exhibitors and 3,000 business meetings, while a total of 1,750 attendees registered for the event.

BIOSPAIN 2016 was attended by a total of 800 private and public entities from 29 countries; 49 parallel and scientific debates were held; and 750 products available for licencing were presented in partnering meetings. These figures have made BIOSPAIN the world’s fifth largest biotechnology event in terms of business meetings and Europe’s most important with a fixed base in a single country.

Another figure to be highlighted from BIOSPAIN 2016 is that in the survey conducted among attendees at the conclusion of the event, 84.81% of respondents said that they had identified real business opportunities. The event was described a “good” or “very good” by 76.92% of attendees.


Congress App

We have an app available for this event on iOS and Android. Its most important functionalities are the assessment of sessions and speakers, a personalised session schedule, questions for speakers, receipt of notifications and satisfaction surveys.


The Platinum sponsors of BIOSPAIN 2018 are PharmaMar and Gilead.


Photo caption: from left to right, Manuel Torralbo, General Secretary of Universities, Research and Technology of the Regional Ministry of Knowledge, Research and University and President of the Andalusian Knowledge Agency; Ion Arocena, General Director of ASEBIO; Julio Coca, General Director of the Innovation and Development Agency of Andalusia (IDEA) and Rafael Solana, Secretary General of Research, Development and Innovation of the Regional Ministry of Health


Lucia Cecilia

Head of Communication ASEBIO and BIOSPAIN 2018

E-mail: lcecilia@asebio.com

Móvil: 663117293

www.asebio.com – www.biospain208.org

For further information:

Press Office – Berbés Asociados – Tel.: 91 563 23 00

María González – 677 456 806 / Sergio López – 630 096 885 / Carmen Rodríguez – 637 798 184

E-mail: mariagonzalez@berbes.com / sergiolopez@berbes.com / carmenrodriguez@berbes.com


BIOSPAIN is present on social media as follows:





Recent Posts

Leave a Comment

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here, or follow this link for more information about cookies.

Aviso de cookies